{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:47:05Z","timestamp":1794005225857,"version":"4.8.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41591-021-01324-7","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T12:22:12Z","timestamp":1619094132000},"page":"802-805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":302,"title":["Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos P.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-0744","authenticated-orcid":false,"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime R.","family":"Merchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-5095","authenticated-orcid":false,"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9249-6338","authenticated-orcid":false,"given":"M. Dror","family":"Michaelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard J.","family":"Appleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Thamake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo F.","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem J.","family":"Zojwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-2806","authenticated-orcid":false,"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"1324_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri, T. K. & Motzer, R. J. Systemic therapy for metastatic renal-cell carcinoma. N. Engl. J. Med. 376, 354\u2013366 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1324_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","volume":"16","author":"WM Linehan","year":"2019","unstructured":"Linehan, W. M. & Ricketts, C. J. The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat. Rev. Urol. 16, 539\u2013552 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"1324_CR3","first-page":"1","volume":"5","author":"TK Choueiri","year":"2020","unstructured":"Choueiri, T. K. & Kaelin, W. G. Targeting the HIF2\u2013VEGF axis in renal cell carcinoma. Nat. Med. 5, 1\u20132 (2020).","journal-title":"Nat. Med."},{"key":"1324_CR4","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2\u03b1 is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).","journal-title":"PLoS Biol."},{"key":"1324_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","volume":"27","author":"VH Haase","year":"2013","unstructured":"Haase, V. H. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 27, 41\u201353 (2013).","journal-title":"Blood Rev."},{"key":"1324_CR6","doi-asserted-by":"publisher","first-page":"e1600","DOI":"10.1038\/cddis.2014.565","volume":"6","author":"J Zhao","year":"2015","unstructured":"Zhao, J., Du, F., Shen, G., Zheng, F. & Xu, B. The role of hypoxia-inducible factor-2 in digestive system cancers. Cell Death Dis. 6, e1600 (2015).","journal-title":"Cell Death Dis."},{"key":"1324_CR7","doi-asserted-by":"crossref","unstructured":"Xu, R. et al. 3-[(1 S,2 S,3 R)-2,3-difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzo nitrile (PT2977), a hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor for the treatment of clear cell renal cell carcinoma. J. Med. Chem. 62, 6876\u20136893 (2019).","DOI":"10.1021\/acs.jmedchem.9b00719"},{"key":"1324_CR8","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.drudis.2019.09.008","volume":"24","author":"Y Yu","year":"2019","unstructured":"Yu, Y., Yu, Q. & Zhang, X. Allosteric inhibition of HIF-2\u03b1 as a novel therapy for clear cell renal cell carcinoma. Drug Discov. Today 24, 2332\u20132340 (2019).","journal-title":"Drug Discov. Today"},{"key":"1324_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney, K. D. et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36, 867\u2013874 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1324_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1200\/JCO.2017.77.5254","volume":"36","author":"WG Kaelin Jr.","year":"2018","unstructured":"Kaelin, W. G. Jr. HIF2 inhibitor joins the kidney cancer armamentarium. J. Clin. Oncol. 36, 908\u2013910 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1324_CR11","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","volume":"76","author":"EM Wallace","year":"2016","unstructured":"Wallace, E. M. et al. A small-molecule antagonist of HIF2\u03b1 is efficacious in preclinical models of renal cell carcinoma. Cancer Res. 76, 5491\u20135500 (2016).","journal-title":"Cancer Res."},{"key":"1324_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1634\/theoncologist.2011-S2-32","volume":"16","author":"A Ravaud","year":"2011","unstructured":"Ravaud, A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16, 32\u201344 (2011).","journal-title":"Oncologist"},{"key":"1324_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.semnephrol.2019.12.009","volume":"40","author":"M Parikh","year":"2020","unstructured":"Parikh, M. & Bajwa, P. Immune checkpoint inhibitors in the treatment of renal cell carcinoma. Semin. Nephrol. 40, 76\u201385 (2020).","journal-title":"Semin. Nephrol."},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1172\/JCI30117","volume":"117","author":"EB Rankin","year":"2007","unstructured":"Rankin, E. B. et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J. Clin. Invest. 117, 1068\u20131077 (2007).","journal-title":"J. Clin. Invest."},{"key":"1324_CR15","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1182\/blood-2004-05-1695","volume":"105","author":"M Scortegagna","year":"2005","unstructured":"Scortegagna, M. et al. HIF-2\u03b1 regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105, 3133\u20133140 (2005).","journal-title":"Blood"},{"key":"1324_CR16","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1164\/rccm.201710-2079OC","volume":"198","author":"Z Dai","year":"2018","unstructured":"Dai, Z. et al. Therapeutic targeting of vascular remodeling and right heart failure in pulmonary arterial hypertension with a HIF-2\u03b1 inhibitor. Am. J. Respir. Crit. Care Med. 198, 1423\u20131434 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1324_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.critrevonc.2017.01.013","volume":"111","author":"O Martinez-Saez","year":"2017","unstructured":"Martinez-Saez, O., Gajate Borau, P., Alonso-Gordoa, T., Molina-Cerrillo, J. & Grande, E. Targeting HIF-2 alpha in clear cell renal cell carcinoma: a promising therapeutic strategy. Crit. Rev. Oncol. Hematol. 111, 117\u2013123 (2017).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1324_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cbpa.2010.03.022","volume":"14","author":"AN Koehler","year":"2010","unstructured":"Koehler, A. N. A complex task? Direct modulation of transcription factors with small molecules. Curr. Opin. Chem. Biol. 14, 331\u2013340 (2010).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"1324_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649\u2013655 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"1324_CR20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau, C., Lee, J. J. & Siu, L. L. Dose escalation methods in phase I cancer clinical trials. J. Natl Cancer Inst. 101, 708\u2013720 (2009).","journal-title":"J. Natl Cancer Inst."}],"updated-by":[{"DOI":"10.1038\/s41591-021-01516-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01324-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01324-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01324-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T11:23:30Z","timestamp":1634210610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01324-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01324-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"9 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-021-01516-1","URL":"https:\/\/doi.org\/10.1038\/s41591-021-01516-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. K. C. has served on advisory boards, provided consultation and received clinical trial grants from AstraZeneca, Bristol Myers Squibb, Exelixis, Pfizer, Janssen, Merck Sharp & Dohme, Eli Lilly, Eisai, Novartis, GlaxoSmithKline, Infinity, Surface Oncology and EMD Serono; has stock ownership in Pionyr and Tempest; has a patent pending and issues related to biomarkers of immuno-oncology; and sits on the National Comprehensive Cancer Network (NCCN) kidney panel. T. K. C. received royalties from Up-To-Date. T. K. C. received fees for continuing medical education (CME)-accredited activities such as Medscape, OncLive, Research to Practice and others. T. M. B. has received research funding from Peloton Therapeutics, a wholly owned subsidiary of Merck & Co., Inc., Daiichi Sankyo, MedPacto, Incyte, Mirati Therapeutics, MedImmune, AbbVie, AstraZeneca, MabVax, Stemline Therapeutics, Merck Sharp & Dohme, Eli Lilly, GlaxoSmithKline, Novartis, Genentech, Deciphera, Merrimack, Immunogen, Phosplatin Therapeutics, Calithera Biosciences, Koltan Pharmaceuticals, Principia Biopharma, Immunocore, Roche, Aileron Therapeutics, Bristol Myers Squibb, Amgen, Onyx, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance Biosciences, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Foundation Medicine, ARMO BioSciences, Leap Therapeutics, Ignyta, Moderna Therapeutics, Pfizer, Loxo and Bayer; has been a consultant for Eli Lilly, Bristol Myers Squibb, Foundation Medicine, Leap Therapeutics, Ignyta, Moderna Therapeutics, Pfizer, Loxo, Bayer, Guardant Health, Exelixis and Blueprint Medicines; and served on speaker bureaus for Bayer and Eli Lilly. K. P. P. has received research funding from Merck Sharp & Dohme, ARMO BioSciences, ArQule, Amgen, Calithera Biosciences, Incyte, Jounce, ADC Therapeutics, 3D Medicines, Syros Pharmaceuticals, Mersana, MabSpace Biosciences, Bayer, Daiichi Sankyo, AnHeart, Basilea, F-star, Linnaeus, Mirati and Tempest Therapeutics; and has served on advisory boards for ArQule, Bayer and Basilea. E. R. P. has received research funding from Peloton Therapeutics, a wholly owned subsidiary of Merck & Co., Inc., Acceleron, AstraZeneca, Bristol Myers Squib, Merck Sharp & Dohme, Pfizer, Astellas and Genentech; has been a consultant for Bristol Myers Squibb, Exelixis, Flatiron, Genentech, Incyte, Janssen, Merck Sharp & Dohme and Seattle Genetics; has served on data safety monitoring committees for AstraZeneca, Infinity Pharma and Pfizer; has a patent pending for methods for screening patients with muscle invasive bladder cancer for responsiveness to neoadjuvant chemotherapy; and has received fees for CME-accredited activities for AUA, Clinical Care Options, Fox Chase Cancer Center, Georgetown, GU ASCO, Medscape, Mt. Sinai School of Medicine, NCCN, Ohio State University, Omniprex, OncLive, PER, PriME Oncology, Research to Practice, Spire Learning and the University of Pennsylvania. J. R. M. has received research funding from Peloton Therapeutics, a wholly owned subsidiary of Merck & Co., Inc., Corvus Pharmaceuticals, Silagen, Tizona, Eisai, Genentech, Pfizer, Vyriad, Replimune, Calithera Biosciences, Rexahn Pharmaceuticals, Seattle Genetics, Astellas, Tocagen, Novartis and Eli Lilly; and has served on an advisory board for Exelixis. D. F. M. has received research funding from Bristol Myers Squibb, Merck Sharp & Dohme, Genentech, Pfizer, Exelixis, X4 Pharma and Alkermes; and has been a consultant for Bristol Myers Squibb, Pfizer, Merck Sharp & Dohme, Alkermes, EMD Serono, Eli Lilly and Iovance Biotherapeutics. M. D. M. has received research funding from Merck Sharp & Dohme and has served on advisory boards for Merck Sharp & Dohme, Pfizer, Novartis, Exelixis and Eisai. L. J. A. has nothing to disclose. S. T. is an employee of Peloton Therapeutics, a wholly owned subsidiary of Merck & Co., Inc. R. F. P. is an employee of and has stock ownership in Merck Sharp & Dohme, a subsidiary of Merck & Co., Inc. N. J. Z. was an employee of Merck & Co., Inc. at the time of this analysis. E.J. has received research funding from Arrowhead Pharmaceuticals, research funding and consultation fees from Aravive, Merck, and Novartis, consultation fees from Aveo, Eisai, Ipsen, NiKang and Pfizer, and has received royalties from UpToDate and consultation fees from Elsevier (PracticeUpdate).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}